Verona Pharma plc VRNA NASDAQ

Verona Pharma plc (VRNA) reported total assets of $474.24M and total liabilities of $269.68M for fiscal year 2024, resulting in total equity of $204.56M.

The company held $399.76M in cash and short-term investments. Total debt stood at $122.7M, with net debt of $-277.06M. The Debt-to-Equity (D/E) ratio was 0.6 (moderate).

Current ratio is 10.63, indicating strong short-term liquidity. Interest coverage is -6.6x (weak).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (53/100) — Total assets $474.24M and equity $204.56M support the company's competitive scale
• VALUE (50/100) — Debt-to-Equity 0.6 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 33/100 with 0/7 criteria passed.

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

PTGX

Protagonist Therapeutics, Inc.

$104.72

+7.33%

APLS

Apellis Pharmaceuticals, Inc.

$40.85

+0.02%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

AKRO

Akero Therapeutics, Inc.

$54.65

+0.00%

MRTX

Mirati Therapeutics, Inc.

$58.70

-0.17%

VKTX

Viking Therapeutics, Inc.

$35.52

+1.46%

IDYA

IDEAYA Biosciences, Inc.

$32.35

-1.43%